Development and Validation of HistoMX, a Gene-Expression Platform for Molecular Interpretation of Kidney Allograft Biopsies
NCT07700563
Antibody Mediated Rejection, BK Virus Nephropathy
View Trial DetailsNCT Number: NCT00205257
Acute rejection is still a major risk factor affecting the prognosis of kidney transplant patients. Alloreactive cells of the recipient infiltrate the kidney graft and cause inflammatory reaction which damages the graft structure and function. Conventional diagnosis of acute rejection is based on clinical symptoms and kidney biopsy examination. The clinical symptoms are a result of the kidney damage, which occurs days after the initiation of the rejection reaction. Kidney biopsy is an invasive and expensive procedure. It has been wished to have new parameters that can replace/supplement the conventional procedures. Chemokines are small molecules that attract inflammatory cells. Changes of chemokine levels in the urine may correlate with the immune status in the kidney. A systematic study to evaluate the chemokine levels in urine and correlation with the kidney biopsy pathology will answer the question whether monitoring of urinary chemokines would be useful in predicting graft rejection/damage.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
Time frame: 1 year
University of Wisconsin, Madison
Other
Prediction of Acute Graft Rejection by Examining Urine Chemokines in Patients With Kidney Transplant
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07700563
Antibody Mediated Rejection, BK Virus Nephropathy
View Trial DetailsNCT05456243
Kidney Transplant
Rochester, Minnesota, United States
View Trial DetailsNCT07621835
CMV Reactivation, CMV Specific Immune Response
Córdoba, Spain
View Trial DetailsNCT04969757
Kidney Transplant
Paris, France
View Trial Details